Increased mitotic activity in the bone marrow is a prerequisite to early-stage differentiated cells in the blood, and occurrence of circulating leukemic blast cells is characteristic for and indicates the existence of acute myeloid or lymphoid leukemia, but also other pathologies such as myelodysplastic syndromes or myeloproliferative neoplasms. 1,2 Malignant leukemia demands timely and correct drug management, which depends on accurate and valid bone marrow and peripheral blood analysis. 3 In the last decades,